Eckert & Ziegler: European Commission confirms European approval for YTTRIGA

Berlin, (PresseBox) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission. Five years ago the European Medicines Agency EMA approved this drug for the first time and as a result of the current renewal process the drug has now been granted an indefinite approval.

YTTRIGA is used as an active component in the preparation of numerous radiopharmaceuticals for the treatment of liver, intestinal and blood cancers as well as for neuroendocrine tumours. YTTRIGA is coupled with a tumour-specific peptide or with an antibody which recognizes cancer cells and binds to them maximizing the dose of ionizing radiation to the cancerous cells and minimizing radiation exposure to healthy cells.

Pharmaceutical grade YTTRIGA is produced under cGMP in Eckert & Ziegler's clean room facility in Braunschweig, from which it is shipped worldwide to radiopharmacy facilities that use it in radiolabeling preparations.

Eckert & Ziegler Strahlen- und Medizintechnik AG

The Eckert & Ziegler Group of Companies has around 540 employees is one of the world's largest providers of isotope technology for radiotherapy and nuclear medicine.

Press releases you might also be interested in

Weitere Informationen zum Thema "Medizintechnik":

So halten Unternehmen die Compliance mit Cognitive Computing ein

Der fol­gen­de Ar­ti­kel von Ste­fan Wel­cker, Ma­na­ging Di­rec­tor DACH, Ex­pert Sys­tem Deut­sch­land, er­läu­tert, warum Au­to­ma­ti­sie­rung im di­gi­ta­len Zei­tal­ter nur mit Cogni­ti­ve Com­pu­ting und Künst­li­cher In­tel­li­genz zu­ver­läs­sig funk­tio­nie­ren kann.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.